A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression

Cancer Cell. 2023 May 8;41(5):986-1002.e9. doi: 10.1016/j.ccell.2023.04.002. Epub 2023 Apr 27.

Abstract

Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer (IBC). Due to a lack of biomarkers able to distinguish high- from low-risk cases, DCIS is treated similar to early IBC even though the minority of untreated cases eventually become invasive. Here, we characterized 115 patient-derived mouse-intraductal (MIND) DCIS models reflecting the full spectrum of DCIS observed in patients. Utilizing the possibility to follow the natural progression of DCIS combined with omics and imaging data, we reveal multiple prognostic factors for high-risk DCIS including high grade, HER2 amplification, expansive 3D growth, and high burden of copy number aberrations. In addition, sequential transplantation of xenografts showed minimal phenotypic and genotypic changes over time, indicating that invasive behavior is an intrinsic phenotype of DCIS and supporting a multiclonal evolution model. Moreover, this study provides a collection of 19 distributable DCIS-MIND models spanning all molecular subtypes.

Keywords: DCIS; MIND; biobank; in vivo; overtreatment; patient-derived models; progression; risk factors.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biological Specimen Banks
  • Biomarkers, Tumor / genetics
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / pathology
  • Carcinoma, Intraductal, Noninfiltrating* / genetics
  • Carcinoma, Intraductal, Noninfiltrating* / pathology
  • Disease Progression
  • Female
  • Heterografts
  • Humans
  • Mice
  • Risk Factors

Substances

  • Biomarkers, Tumor